Form 4: Boston Scientific Director Sells Shares Under Pre-Planned Arrangement

Boston Scientific Director Yoshiaki Fujimori reported the sale of 2,901 shares of common stock at $106.99 per share, reducing his direct beneficial ownership to 2,081 shares, as part of a Rule 10b5-1 pre-planned transaction scheduled for July 29, 2025.

Summary

• Yoshiaki Fujimori, a Director of Boston Scientific Corp (BSX), reported a transaction involving the disposition (sale) of shares.
• The transaction entails the sale of 2,901 shares of Common Stock.
• The sale price per share was $106.99.
• Following this transaction, Mr. Fujimori will directly own 2,081 shares of Common Stock.
• The reported transaction date is July 29, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan, indicating it was pre-planned.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, although the pre-planned nature (Rule 10b5-1) mitigates some of the negative implications, suggesting the sale is not based on new, adverse information.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-planned and not based on immediate, non-public information, which enhances transparency.

Negatives

• A Director sold 2,901 shares of company common stock.
• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces management's direct stake in the company.

Risks

• Potential negative market perception due to insider selling, which could lead to short-term stock price volatility.

Future Outlook

NA

Industry Context

This filing is specific to an individual insider transaction and does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the director's sale as a signal, potentially leading to negative sentiment or a slight downward pressure on the stock price, though the 10b5-1 plan lessens the impact.

Key Dates

Recommendation

While insider selling can be a negative signal, the transaction was conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on new, material non-public information. This mitigates the negative impact, but the sale still represents a reduction in direct insider ownership. Without further company-specific or industry-wide information, a 'hold' recommendation is appropriate, advising investors to monitor future developments.

Keywords

Boston Scientific, BSX, Form 4, Insider Trading, Director, Stock Sale, Yoshiaki Fujimori, Rule 10b5-1